| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/24/2004 | WO2003092736A3 Peptide nucleic acid conjugates with transporter peptides |
| 06/24/2004 | WO2003092580B1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 06/24/2004 | WO2003061559A9 Binding peptides specific for the extracellular domain of erbb2 and uses therefor |
| 06/24/2004 | WO2003047589A8 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
| 06/24/2004 | WO2002040056A9 Carrageenan viscoelastics for ocular surgery |
| 06/24/2004 | US20040122214 Glycoprotein conjugate for the prevention lymphadenopathy associated viral infection; viricides |
| 06/24/2004 | US20040122165 Hydrogel-forming system with hydrophobic and hydrophilic components |
| 06/24/2004 | US20040122106 rapidly disintegrates in the oral cavity without water and has a practical hardness; comprises a water soluble active ingredient, D-mannitol in the form of crystals or fine particles and crospovidone |
| 06/24/2004 | US20040122105 Transdermal compositions |
| 06/24/2004 | US20040122086 Method for the production of anhydrous, pharmaceutical formulations of xanthogenates |
| 06/24/2004 | US20040122081 Intravenous formulation for a taxoid antitumor agent as a two-vial kit with the taxoid, solvent and buffer in one vial and cosolvent and buffer in the other; mixing prior to administration; improved solubility, stability and oxidation resistance |
| 06/24/2004 | US20040122071 Fluconazole, a compound selected from a group consisting of fatty acid, fatty alcohol, higher fatty acid ester and lower alcohol and a base; favorable absorption and delivery through the human skin; low skin stimulation; stability; spreading |
| 06/24/2004 | US20040121993 for the reduction of cholesterol in blood, and treatment of fatty liver, hyperglycemia and diabetes |
| 06/24/2004 | US20040121954 Poly(dipeptide) as a drug carrier |
| 06/24/2004 | US20040121944 Cyclosporin-based pharmaceutical compositions |
| 06/24/2004 | US20040121942 Inducing phospholamban deficiency for therapy of heart failure |
| 06/24/2004 | US20040121940 Anticancer prodrugs, enhance enzymatic activation rates |
| 06/24/2004 | US20040121426 Process for preparing albumin protein conjugated oligonucleotide probes |
| 06/24/2004 | US20040121415 Monovalent antibody fragments |
| 06/24/2004 | US20040121028 Plant based agents as bioavailability / bioefficacy enhancers for drugs and nutraceuticals |
| 06/24/2004 | US20040121019 Particles comprising a biopolymer which is degradable under the effect of an electromagnetic wave as emitted by a solar radiation |
| 06/24/2004 | US20040121012 Sustained release matrix for high-dose insoluble drugs |
| 06/24/2004 | US20040121011 Methods for making and delivering Rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof |
| 06/24/2004 | US20040121009 Method of modifying the release profile of sustained release compositions |
| 06/24/2004 | US20040121008 Process for producing sustained release preparation |
| 06/24/2004 | US20040121005 Porous COX-2 inhibitor matrices and methods of manufacture thereof |
| 06/24/2004 | US20040121000 Ingestible compositions containing an odoriferous oil |
| 06/24/2004 | US20040120999 Liposome containing remedy for vascular disease |
| 06/24/2004 | US20040120997 liposomes containing a sterol skeleton based compound wherein one or several amphoteric groups with an isoelectric point of between 4 and 9 are substituted on the 3rd position of the ring system |
| 06/24/2004 | US20040120996 administering as a transdermal patch, containing oxybutynin to a patient a duration about 24 to 96 hours to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from 0.5:1 to 5:1 to treat overactive bladder |
| 06/24/2004 | US20040120994 polymer matrix contains the sex hormone testosterone and a mixture of a penetration-enhancing substance selected from fatty alcohol esters and fatty acid esters, and at least one readily volatile penetration-enhancing agent |
| 06/24/2004 | US20040120990 Absorbent proteins and methods for using same |
| 06/24/2004 | US20040120986 acidic beverages and oral healthcare compositions; use of calcium in such compositions to alleviate or prevent the tooth damage associated with the consumption of acid |
| 06/24/2004 | US20040120979 Delivery systems comprising biocompatible and bioerodable membranes |
| 06/24/2004 | US20040120971 Biodegradable carrier and method for preparation thereof |
| 06/24/2004 | US20040120965 Method to reduce the physiologic effects of drugs on mammals |
| 06/24/2004 | US20040120958 Modified antibodies to prostate-specific membrane antigen and uses thereof |
| 06/24/2004 | US20040120949 antibodies conjugated to cytotoxic compounds and radiotherapy in cancer therapy |
| 06/24/2004 | US20040120910 Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks |
| 06/24/2004 | US20040120904 Delivery system for functional compounds |
| 06/24/2004 | US20040120891 Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| 06/24/2004 | US20040119179 Method for making very fine particles consisting of a principle inserted in a host molecule |
| 06/24/2004 | US20040118414 Surface modified viscoelastics for ocular surgery |
| 06/24/2004 | DE10257240A1 Kosmetische Zusammensetzung mit elektrischen Ladungsträgern Cosmetic composition with electrical charge carriers |
| 06/24/2004 | DE10256982A1 New epithilone derivatives are useful for the treatment of diseases associated with proliferative diseases e.g. tumor diseases, inflammatory diseases and neurodegenerative diseases |
| 06/24/2004 | DE10256900A1 Tumorspezifische Erkennungsmoleküle Tumor-specific recognition molecules |
| 06/24/2004 | DE10256774A1 Medicament for transmucosal or transdermal drug administration, containing combination of monoterpene and polyol, e.g. menthol and propanediol, as resorption improvers |
| 06/24/2004 | DE10253773B3 Use of acesulfamic acid as acidulant, useful in foods, beverages, pharmaceuticals and cosmetics, provides lower pH than standard food acids at equal acidic taste |
| 06/24/2004 | CA2509400A1 Nk cell receptor conjugates for treating malignancies |
| 06/24/2004 | CA2508441A1 Propofol-containing fat emulsions |
| 06/24/2004 | CA2507573A1 Nucleic acid labeling compounds |
| 06/23/2004 | EP1431347A1 Composition containing fine particles for supporting biologically active substance thereon or having the same supported thereon and method for preparing these |
| 06/23/2004 | EP1431291A1 1-Aryl-4-cyano-3-cyclopropylpyrazole derivatives as ectoparasiticidal agents |
| 06/23/2004 | EP1430906A2 Nanoscale hydrogels against wrinkles, rough and dry skin |
| 06/23/2004 | EP1430897A2 Opioid formulations having extended controlled release |
| 06/23/2004 | EP1430896A1 NICOTINE−CONTAINING FILM PREPARATION |
| 06/23/2004 | EP1430895A1 Novel substituted benzimidazole dosage forms and method of using same |
| 06/23/2004 | EP1430892A1 Aqueous ecabet sodium solution preparation |
| 06/23/2004 | EP1430891A1 Oil-acid-emulsion for the treatment of joint diseases and for the stimulation of blood-circulation |
| 06/23/2004 | EP1430889A1 Edible coating composition |
| 06/23/2004 | EP1430887A1 Powder for inhalation containing Tiotropium |
| 06/23/2004 | EP1430157A2 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/23/2004 | EP1430117A2 Plasticized hydrophilic glasses for improved stabilization of biological agents |
| 06/23/2004 | EP1430085A1 Leukocyte inactivation module |
| 06/23/2004 | EP1430082A2 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| 06/23/2004 | EP1430074A1 Aminoglycoside lipid derivatives for transfection |
| 06/23/2004 | EP1430067A2 Eukaryotic cells and method for preserving cells |
| 06/23/2004 | EP1429915A1 Systems, methods and apparatuses for manufacturing dosage forms |
| 06/23/2004 | EP1429914A1 Systems, method and apparatuses for manufacturing dosage forms |
| 06/23/2004 | EP1429844A2 Conjugated anti-psychotic drugs and uses thereof |
| 06/23/2004 | EP1429810A1 Transporting of taxoid derivatives through the blood brain barrier |
| 06/23/2004 | EP1429808A1 Solid composition containing bacillus-type non-pathogenic bacterial spores |
| 06/23/2004 | EP1429802A1 Delivery system for biological component |
| 06/23/2004 | EP1429797A2 Diagnosis and treatment of malignant neoplasms |
| 06/23/2004 | EP1429792A1 Strontium compound for treatment of sub-dermal soft tissue pain |
| 06/23/2004 | EP1429785A1 Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier |
| 06/23/2004 | EP1429781A2 Composition comprising nanoparticulate spironolactone |
| 06/23/2004 | EP1429780A1 Method of treating middle ear infections |
| 06/23/2004 | EP1429774A2 Stent coated with a substained-release drug delivery |
| 06/23/2004 | EP1429770A1 New formulations and use thereof |
| 06/23/2004 | EP1429769A1 New formulations and use thereof |
| 06/23/2004 | EP1429768A1 Novel medicaments for inhalation |
| 06/23/2004 | EP1429766A1 Pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments |
| 06/23/2004 | EP1429749A2 Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| 06/23/2004 | EP1429748A1 Solid compositions comprising ramipril |
| 06/23/2004 | EP1429747A1 Core formulation comprising pioglitazone hydrochloride and a biguanide |
| 06/23/2004 | EP1429746A2 Dosage forms having an inner core and outer shell |
| 06/23/2004 | EP1429745A2 Composite dosage forms having an inlaid portion |
| 06/23/2004 | EP1429743A1 Dosage forms having an inner core and outer shell with different shapes |
| 06/23/2004 | EP1429742A2 Modified release dosage forms |
| 06/23/2004 | EP1429741A1 Process for coating solid particles |
| 06/23/2004 | EP1429740A1 Core formulation comprising troglitazone and a biguanide |
| 06/23/2004 | EP1429738A2 Modified release dosage forms |
| 06/23/2004 | EP1429737A1 Modified release dosage forms |
| 06/23/2004 | EP1429736A2 Organoleptically acceptable intraorally disintegrating compositions |
| 06/23/2004 | EP1429733A1 Preparation of microparticles |
| 06/23/2004 | EP1429732A1 A core formulation |
| 06/23/2004 | EP1429731A1 Nanoparticulate insulin formulations |
| 06/23/2004 | EP1429730A2 Opioid formulations having reduced potential for abuse |
| 06/23/2004 | EP1429728A1 Sustained release preparations |